AEST.MED.INT.HLD.SP.ADR/3 (3FMA) - Net Assets
Based on the latest financial reports, AEST.MED.INT.HLD.SP.ADR/3 (3FMA) has net assets worth €-43.23 Million EUR (≈ $-50.54 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€510.89 Million ≈ $597.29 Million USD) and total liabilities (€554.12 Million ≈ $647.83 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check AEST.MED.INT.HLD.SP.ADR/3 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-43.23 Million |
| % of Total Assets | -8.46% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 245.19 |
AEST.MED.INT.HLD.SP.ADR/3 - Net Assets Trend (2021–2025)
This chart illustrates how AEST.MED.INT.HLD.SP.ADR/3's net assets have evolved over time, based on quarterly financial data. See AEST.MED.INT.HLD.SP.ADR/3 (3FMA) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for AEST.MED.INT.HLD.SP.ADR/3 (2021–2025)
The table below shows the annual net assets of AEST.MED.INT.HLD.SP.ADR/3 from 2021 to 2025. For live valuation and market cap data, see 3FMA market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €-43.23 Million ≈ $-50.54 Million |
-562.58% |
| 2024-12-31 | €9.35 Million ≈ $10.93 Million |
-72.21% |
| 2023-12-31 | €33.63 Million ≈ $39.32 Million |
+126.72% |
| 2022-12-31 | €-125.88 Million ≈ $-147.17 Million |
+32.48% |
| 2021-12-31 | €-186.42 Million ≈ $-217.95 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to AEST.MED.INT.HLD.SP.ADR/3's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 18697100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €1.23 Billion | % |
| Total Equity | €-20.60 Million | 100.00% |
AEST.MED.INT.HLD.SP.ADR/3 Competitors by Market Cap
The table below lists competitors of AEST.MED.INT.HLD.SP.ADR/3 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Azitra Inc
NYSE MKT:AZTR
|
$3.30 Million |
|
NextEnergy Solar Fund Ltd
LSE:NESF
|
$3.30 Million |
|
Halo Technologies Holdings Ltd
AU:HAL
|
$3.31 Million |
|
WestKam Gold Corp
V:WKG
|
$3.31 Million |
|
Addentax Group Corp
NASDAQ:ATXG
|
$3.30 Million |
|
Albion Enterprise VCT PLC
LSE:AAEV
|
$3.29 Million |
|
Marvel Discovery Corp
V:MARV
|
$3.29 Million |
|
Harris Technology Group Ltd
AU:HT8
|
$3.29 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AEST.MED.INT.HLD.SP.ADR/3's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 30,457,000 to -20,600,000, a change of -51,057,000 (-167.6%).
- Net loss of 53,347,000 reduced equity.
- Other factors increased equity by 2,290,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-53.35 Million | -258.97% |
| Other Changes | €2.29 Million | +11.12% |
| Total Change | €- | -167.64% |
Book Value vs Market Value Analysis
This analysis compares AEST.MED.INT.HLD.SP.ADR/3's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €-2.22 | €0.06 | x |
| 2022-12-31 | €-1.21 | €0.06 | x |
| 2023-12-31 | €0.34 | €0.06 | x |
| 2024-12-31 | €0.21 | €0.06 | x |
| 2025-12-31 | €-0.14 | €0.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AEST.MED.INT.HLD.SP.ADR/3 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -7.38%
- • Asset Turnover: 1.41x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-28.41%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | -90.87% | 1.12x | 0.00x | €-570.95 Million |
| 2022 | 0.00% | -11.38% | 1.23x | 0.00x | €-64.88 Million |
| 2023 | -76.57% | -5.48% | 1.22x | 11.47x | €-42.32 Million |
| 2024 | -65.49% | -2.64% | 1.55x | 15.96x | €-22.99 Million |
| 2025 | 0.00% | -7.38% | 1.41x | 0.00x | €-51.29 Million |
Industry Comparison
This section compares AEST.MED.INT.HLD.SP.ADR/3's net assets metrics with peer companies in the Medical Care Facilities industry.
Industry Context
- Industry: Medical Care Facilities
- Average net assets among peers: $6,479,078,944
- Average return on equity (ROE) among peers: -87.01%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AEST.MED.INT.HLD.SP.ADR/3 (3FMA) | €-43.23 Million | 0.00% | N/A | $3.30 Million |
| China Resources Medical Holdings Company Limited (1PH) | $6.14 Billion | 6.37% | 0.28x | $405.05 Million |
| JINXIN FERT.GRP HD-00001 (3NX) | $10.19 Billion | 3.38% | 0.46x | $656.44 Million |
| REVITALIST L.A.W. LTD (4DO) | $1.87 Million | -771.24% | 4.54x | $744.60K |
| Wenzhou Kangning Hospital Co. Ltd (4WK) | $1.21 Billion | 6.69% | 0.53x | $17.43 Million |
| HYGEIA HC HLDGS DL-00001 (50I) | $6.67 Billion | 8.96% | 0.64x | $9.61K |
| COMPASS PATHW SP.ADR (5Y6) | $225.74 Million | -52.48% | 0.22x | $657.30 Million |
| Bumrungrad Hospital Public Company Limited (BZ7A) | $31.17 Billion | 24.10% | 0.17x | $50.75K |
| Eifelhöhen-Klinik AG (EIF) | $9.88 Million | -19.11% | 6.64x | $10.05 Million |
| Fresenius Medical Care AG & Co. KGaA (FME) | $2.70 Billion | 10.24% | 1.40x | $10.01 Billion |
About AEST.MED.INT.HLD.SP.ADR/3
Aesthetic Medical International Holdings Group Limited provides aesthetic medical services in the People's Republic of China. The company offers surgical aesthetic treatments, such as eye surgery, rhinoplasty, breast augmentation, and liposuction; and non-surgical aesthetic treatments, including minimally invasive and energy-based treatments, which include laser, ultrasound, and radiofrequency tr… Read more